HARVARD BIOSCIENCE INC - 8-K Filing
Harvard Bioscience filed an 8-K to disclose a corporate slide presentation outlining FY25 results of $87M in revenue and adjusted EBITDA of $8M, with guidance for 2-4% growth in FY26. The company also announced strategic actions including appointing John Duke as CEO effective July 2025, expanding its board, refinancing debt to extend maturity until December 2029, and a manufacturing consolidation plan (Project Viking) expected to generate $3M of adjusted EBITDA savings in FY2027 and $4M starting in FY2028. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $HBIO